Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,464,710
  • Shares Outstanding, K 28,748
  • Annual Sales, $ 234,600 K
  • Annual Income, $ -13,230 K
  • EBIT $ 48 M
  • EBITDA $ 46 M
  • 60-Month Beta 0.40
  • Price/Sales 8.27
  • Price/Cash Flow N/A
  • Price/Book 50.24

Options Overview Details

View History
  • Implied Volatility 84.98% (+84.98%)
  • Historical Volatility 100.24%
  • IV Percentile 60%
  • IV Rank 24.99%
  • IV High 161.61% on 09/24/25
  • IV Low 59.45% on 12/22/25
  • Expected Move (DTE 24) 5.70 (10.99%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 74
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 1,089
  • Open Int (30-Day) 641
  • Expected Range 46.13 to 57.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.77
  • Number of Estimates 7
  • High Estimate $0.46
  • Low Estimate $-1.56
  • Prior Year $-1.28
  • Growth Rate Est. (year over year) +39.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.00 +17.77%
on 04/20/26
73.30 -29.30%
on 04/13/26
-10.55 (-16.91%)
since 03/20/26
3-Month
44.00 +17.77%
on 04/20/26
73.30 -29.30%
on 04/13/26
+5.14 (+11.01%)
since 01/21/26
52-Week
17.11 +202.93%
on 09/16/25
73.30 -29.30%
on 04/13/26
+31.20 (+151.31%)
since 04/21/25

Most Recent Stories

More News
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Focused on protecting and returning value of  Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately...

ANAB : 51.82 (+1.71%)
TRAX : 17.00 (-8.60%)
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market Stockholders will receive one share of First Tracks Bio common stock for every one...

ANAB : 51.82 (+1.71%)
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026...

ANAB : 51.82 (+1.71%)
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and...

ANAB : 51.82 (+1.71%)
TRAX : 17.00 (-8.60%)
Upwing Energy Achieves ISO 9001:2015 Certification for Production of its Subsurface Compressor System

Upwing Energy, a leader in advanced compression technology for the oil and gas industry, has achieved ISO 9001:2015 certification for the production of its Subsurface Compressor Systems for improved natural...

ANAB : 51.82 (+1.71%)
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease...

ANAB : 51.82 (+1.71%)
Anaptys Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 51.82 (+1.71%)
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage...

ANAB : 51.82 (+1.71%)
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 51.82 (+1.71%)
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving

AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall...

ANAB : 51.82 (+1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 59.24
2nd Resistance Point 57.03
1st Resistance Point 54.43
Last Price 51.82
1st Support Level 49.62
2nd Support Level 47.41
3rd Support Level 44.81

See More

52-Week High 73.30
Fibonacci 61.8% 51.83
Last Price 51.82
Fibonacci 50% 45.20
Fibonacci 38.2% 38.57
52-Week Low 17.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.